Findings from a phase III clinical trial for advanced lung cancer patients could help oncologists better predict which patients are likely to receive the most benefit from immunotherapy as a first-line treatment based on the unique molecular characteristics of their tumor, according to a new study reported by a global team led by David Carbone of Ohio State University Comprehensive Cancer–Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.
Tagrisso (osimertinib) plus chemotherapy delivers a statistically significant and clinically meaningful survival benefit compared to Tagrisso monotherapy in the first-line treatment of patients with locally advanced or metastatic epidermal growth factor receptor-mutated non-small cell lung cancer, according to results from the final overall survival analysis of the FLAURA2 phase III trial.
